Please visit the website origingenomics.com. Here you will see why the need for a new logo....Thank you for your help!
Also, please visit it's sister company http://www.origincbd.com for the potential of continuing the continuity of the concept.
Origin’s core philosophy is married to its understanding of the profound medicinal value of the Cannabis Sativa plant. The entirety of Origin’s management team and advisory board have first hand knowledge of the healing properties of Cannabis Sativa. It is these accumulated experiences that push Origin to help propel the plant’s mountain of anecdotal evidence to verifiable clinical proof so that it can enter into the accepted public domain of medicine where it so rightly belongs.
Origin firmly agrees with the medical community’s thought leaders that modern medicine is being exponentially driven into the era of Pharmacogenomics; targeted and individualized therapies rooted in genomics and DNA sequencing. Origin Genomics formulates, based upon an individual’s, genomic make up, ailment(s), medical history and ongoing lab results, specific, cannabinoid medicines to either alleviate symptoms of and on occasion cure certain disease states.
FOR GREATER CLARITY
Pharmacogenomics is the study of how genes affect a person’s response to drugs. This new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup.
Many drugs that are currently available are “one size fits all,” but they don’t work the same way for everyone. It can be difficult to predict who will benefit from a medication, who will not respond at all, and who will experience negative side effects. Adverse drug reactions are a significant cause of hospitalizations and deaths in the United States. With the knowledge gained from the Human Genome Project, researchers are learning how inherited differences in genes affect the body’s response to medications.
The field of pharmacogenomics is still in its infancy and its use is currently quite limited, but new approaches are under study in clinical trials. In the future, pharmacogenomics will allow the development of tailored drugs to treat a wide range of health problems.